Development of pulmonary hypertension after initiation of diazoxide for the treatment of neonatal hyperinsulinemic hypoglycemia is a rare, but previously described association. Risk factors for development of diazoxide-associated pulmonary hypertension include lower gestational age and congenital heart disease. This novel case report describes an infant with noncompaction cardiomyopathy who developed pulmonary hypertension shortly after initiation of diazoxide for hyperinsulinemic hypoglycemia which resolved upon cessation of the drug. This case highlights the benefit of having pre-treatment knowledge of underlying cardiac anatomy and makes a case for routine echocardiographic screening for neonates initiating diazoxide treatment.
CITATION STYLE
Sullivan, R. T., Tillman, K. A., Kindel, S. J., & Handler, S. S. (2021). Diazoxide-associated pulmonary hypertension in a patient with noncompaction cardiomyopathy. Pulmonary Circulation, 11(1). https://doi.org/10.1177/2045894020987117
Mendeley helps you to discover research relevant for your work.